Teva Pharm, Intel to study Huntington disease progression

A sign bearing the logo of Teva is seen in Jerusalem

Teva Pharm, Intel to study Huntington disease progression

Teva and Intel are joining forces on a wearable device and machine-learning platform to improve the understanding and treatment of Huntington's disease. Patients generally succumb to the disease within 15 to 25 years of the diagnosis.

The platform will monitor and analyse key symptoms that impact daily living to better understand disease progression and improve treatment evaluation, Israel-based Teva, the world's largest generic drugmaker, said. The study is poised to launch near the end of the year in the US and Canada, Teva said Thursday.

Specifically, patients will wear a smartwatch outfitted with sensors that will continuously measure their general functioning and movement. They hope to launch the study in the US and Canada by the end of the year.

The duo plans to deploy the platform, which will enable continuous monitoring and analysis of Huntington's symptoms, in a substudy in an ongoing Phase II trial of the drug pridopidine in people with Huntington's, according to a statement. This project aims to provide objective and continuous data on Huntington's patients and the effects of treatment on them, he said.

"Current measurement of symptoms is largely based on observation when the patient sees the doctor", said Michael Hayden, president of Teva Global R&D.

This cloud-based solution for analyzing wearable device data is being developed using the open-source Intel Trusted Analytics Platform (TAP), a software platform to accelerate the creation of advanced analytics and machine learning solutions. "The complexity of analyzing these data streams requires a platform for machine learning, to help drive the pharmaceutical industry towards faster, better clinical trials, potentially leading to new treatments for patients".

Altre Notizie